David Einhorn's BIO Position Overview
David Einhorn (via Dme Capital Management, Lp) currently holds 103,990 shares of Bio-Rad Laboratories, Inc. (BIO) worth $39.28 M, representing 1.11% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.
Based on recent 13F filings, David Einhorn has initiated a new position in BIO, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
David Einhorn's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by David Einhorn
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +103,990 | New Buy | 103,990 | $377.71 |
David Einhorn's Bio-Rad Laboratories Investment FAQs
David Einhorn first purchased Bio-Rad Laboratories, Inc. (BIO) in Q3 2026, acquiring 103,990 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn has held Bio-Rad Laboratories, Inc. (BIO) for 1 quarters since Q3 2026.
David Einhorn's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q3 2026, adding 103,990 shares worth $39.28 M.
According to the latest 13F filing for Q3 2026, David Einhorn's firm, Dme Capital Management, Lp, owns 103,990 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $39.28 M.
As of the Q3 2026 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 1.11% of David Einhorn's publicly disclosed stock portfolio, making it one of their key holdings.
David Einhorn's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 103,990 shares, as reported at the end of Q3 2026.